Deafness
Eli Lilly Partners with Seamless Therapeutics on Up to $1.12B Recombinase Gene Editing Deal for Hearing Loss
Eli Lilly; Seamless Therapeutics; recombinase; gene editing; hearing loss; collaboration; $1.12B
Regeneron Heads to FDA Seeking Approval for Game-Changing Hearing Loss Gene Therapy
Regeneron; hearing loss; gene therapy; DB-OTO; FDA approval; OTOF gene; CHORD trial
Eli Lilly Expands RNA Pipeline with $1.3 Billion Rznomics Hearing Loss Pact
Eli Lilly; Rznomics; RNA editing; hearing loss; gene therapy; pharmaceutical partnerships; biotech; trans-splicing ribozyme; sensorineural hearing loss; RNA therapeutics